HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PAVM
PAVmed Inc.
There isn't enough reported data to score PAVM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PAVM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
PAVM's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PAVM PE Valuation
PAVM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PAVM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PAVM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
PAVM has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus PAVM down 107%.
PAVM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$129.90 | +$189.83 |
| Q2 2024 | -$245.10 | +$133.13 |
| Q1 2024 | -$272.40 | +$173.33 |
| Q4 2023 | -$274.80 | +$179.93 |
| Q3 2023 | -$319.73 | +$134.77 |
| Q2 2023 | -$378.23 | +$13.27 |
| Q1 2023 | -$445.73 | -$121.73 |
| Q4 2022 | -$454.73 | -$162.23 |
PAVM is still losing money, but far less than before: $16.54 per share over the past year, against $454.73 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PAVM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PAVM on profitability, with a higher operating margin.
PAVM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33K | +450% |
| Q1 2026 | $22K | +175% |
| Q3 2025 | $5K | -100% |
| Q2 2025 | $6K | -99% |
| Q1 2025 | $8K | -99% |
| Q3 2024 | $1M | +26% |
| Q2 2024 | $1M | +502% |
| Q1 2024 | $1M | +124% |
PAVM's revenue is recovering but still below its 2023 peak: $33,000 last quarter, up 450% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -21279% | +57305 points |
| Q1 2026 | -36523% | +31552 points |
| Q4 2025 | -13083% | N/A |
| Q3 2025 | -96880% | -95722 points |
| Q2 2025 | -78583% | -77215 points |
| Q1 2025 | -68075% | -66671 points |
| Q3 2024 | -1158% | +805 points |
| Q2 2024 | -1368% | +8562 points |
PAVM's operating margin was −21279% last quarter, up 57305 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PAVM on cash generation, producing positive trailing cash flow while its opponent burns cash.
PAVM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -$1.5M |
| Q1 2026 | -$2.6M | -$1.1M |
| Q4 2025 | -$1.6M | -1839% |
| Q3 2025 | -$899K | +$8M |
| Q2 2025 | -$1.2M | +$10.5M |
| Q1 2025 | -$1.6M | +$11.6M |
| Q4 2024 | $90K | +$12.1M |
| Q3 2024 | -$8.9M | +$2.2M |
PAVM has burned cash in almost every quarter: −$8M over the past year, against −$12M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PAVM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PAVM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +297% | +4.7M shares |
| 1 year | +940% | +5.7M shares |
| 3 years | +3067% | +6.1M shares |
| 5 years | +5731% | +6.2M shares |
| Available history | +8992% | +6.2M shares |
PAVM has 6M diluted shares, up 940% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PAVM Net Leverage
PAVM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PAVM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.8 | Oversold |
| Stochastic | 2.5 | Oversold |
PAVM's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PAVM PE vs Healthcare Sector
PAVM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PAVM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.37 | 43% below |
| 20 week MA | $3.97 | 66% below |
| 50 week MA | $6.56 | 80% below |
| 100 week MA | $12.0 | 89% below |
| 200 week MA | $59.1 | 98% below |
PAVM is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over PAVM on returns for 2026, with the stronger performance.
PAVM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $517.5 | $877.5 | +70% |
| 2021 | $877.5 | $1,242.0 | +42% |
| 2022 | $1,242.0 | $227.3 | -82% |
| 2023 | $227.3 | $123.6 | -46% |
| 2024 | $123.6 | $19.4 | -84% |
| 2025 | $19.4 | $8.68 | -55% |
| 2026 YTD | $8.68 | $1.34 | -85% |
PAVM has finished four years in a row lower, and it's down 85% so far in 2026.